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A person experiencing more than one medical condition may have ambiguous clinical presentation. ITP is a serious autoimmune
disease with little epidemiological evidence on its burden, risk factors, and comorbidities. Using the United Kingdom general
practice research database, we conducted a 14 years population-based case control-type study to explore medical conditions more
likely to cooccur with ITP and their temporal relationship in association with ITP. ITP patients were matched to non-ITP on
practice, age, gender, and follow-up period. Potential comorbidities were represented by patients’ medical information at the
preferred term level of the MedDRA international classiﬁcation. As well as death (OR = 60.0; 95% CI [4.47–806.0]) and known
clinical signs and symptoms of ITP, ITP is associated with considerable number of medical conditions. The association between
ITP and some of these conditions is apparent both before and after ITP diagnosis. Speciﬁc targeted studies can now be setup to
reexamine observed associations.
Copyright © 2009 M. A. Feudjo-Tepie et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Idiopathicthrombocytopenicpurpura(ITP)isaseriousacq-
uired autoimmune disorder characterized by a low platelet
count (thrombocytopenia) and mucocutaneous bleeding
[1]. It is commonly assumed that ITP results from autoan-
tibodies causing accelerated platelet destruction. Recent data
suggest that autoantibodies may also inhibit platelet produc-
tion [2]. The diagnosis of ITP is complex and is very often
based on the exclusion of other causes of thrombocytopenia
[3–6].
ITP is traditionally divided into acute and chronic forms,
based on the duration of thrombocytopenia (i.e., less than 6
months for acute and more than 6 months for chronic) [5].
ITP is generally acute in young children and typically, occurs
a few days to a few weeks after an infection (e.g., varicella
zoster virus). ITP in children is thought to be a benign
and self-limiting disorder with an excellent prognosis. In
contrast, ITP in adults is primarily chronic, and the onset is
oftenasymptomatic.Thediseaseismoreprevalentinfemales
than males [4].
There is relatively little epidemiological evidence on
disease burden and risk factors; prevalence in adults and
childrenmayrangefrom9.6to189per100000person[7–9].
Frederiksen and Schmidt [7] estimated incidence of 2.7 per
100000 person per year in Denmark. Our recent estimation
of the prevalence of chronic ITP in the United State using a
large U.S. claim database gave 20.3 per 100000 person [10].
The coexistence in an individual with two (or more)
medical conditions is commonly referred to as comorbidity.
More speciﬁcally, Feinstein [11] deﬁnes comorbidity as “any
distinct additional clinical entity, that has existed or that
may occur during the clinical course of a patient who has
the index disease under study.” A person experiencing more
than one condition may present with an ambiguous clinical
presentation [12]. Thus, knowledge of disease comorbidities2 Advances in Hematology
can provide a better understanding of disease burden as
well as inform diagnosis and treatment decisions. For
example, the investigation of idiopathic normal pressure
hydrocephalus (INPH) comorbidities conﬁrmed the early
suspicions of INPH as a multi-aetiological clinical entity
possibly overlapping physiologically with cerebrovascular
and Alzheimer diseases [13]. Disease comorbidities also
have consistently been shown to be important prognostic
factors of a number of health conditions including cancer,
independent of the tumour stage [14–18]. Colinet et al.
[19] suggested that comorbidities may explain in part the
v a r i a b i l i t yi ns u r v i v a lo b s e r v e df r o ms t a g eIn o n s m a l lc e l l
lung cancer. So, the importance of comorbidity studies
is well acknowledged in the literature and their use well
documented.
However, evidence on ITP speciﬁc comorbidities is
sparse. Indeed, apart from the known symptoms of the
disease (i.e., bleeding, petechia, purpura, etc), to our knowl-
edge, there is little empirical evidence in the literature on
the association, or lack of it, between ITP and other medical
conditions. Knowledge of ITP speciﬁc comorbidities, that is
those frequently occurring with ITP, may provide a better
understanding of ITP disease progression, ITP disease bur-
den, and could inform treatment decisions. Their knowledge
might lead to preventive measures, early diagnoses, and
better disease management. Comorbidities of ITP can also
help put into context potential safety signals and improve
clinical trial design and planning. Hence, using “real world”
evidence, this study aims to reduce the knowledge gap. More
speciﬁcally, using a large UK healthcare database, the paper
describes the basic characteristics of an ITP population and
identiﬁes other medical conditions more likely to cooccur or
to be diagnosed with ITP. Furthermore, comparing the ITP
cohort to a matched non-ITP cohort, the study investigates
potential temporal relationship in the association between
identiﬁed comorbidities and ITP.
2.MaterialandMethod
2.1. Data Source. The study population includes patients
r e g i s t e r e do nU K ’ sg e n e r a lp r a c t i c er e s e a r c hd a t a b a s e
(GPRD) during the period 1990–2004. The GPRD has
been described elsewhere [20, 21] and has previously been
used to study comorbidities of newly diagnosed COPD
and asthma [22] among other things. Brieﬂy, the GPRD
contains detailed information on diagnoses, prescribing, GP
investigations, outcomes, and hospital referrals, together
with basic demographic information for about 6 million
patients from more than 370 representative general practices
throughout the UK. The database is population-based and
representative of the age, sex, and geographic regions of the
UK [21]. Data quality is monitored continuously by the
UK Medicines and Healthcare products Regulatory Agency
(MHRA), and practices that fail to maintain the required
standards are removed. The completeness and accuracy of
the recording of medical information have been validated
[23–26].Thisstudywasapprovedbythescientiﬁcethicaland
advisory group for the GPRD.
2.2. Study Design and Case Deﬁnition. A case control study-
type approach was utilized. ITP patients (cases) were iden-
tiﬁed using READ or OXMIS codes (contact authors for
details). Patients with less than 1 year of follow-up before or
after the ﬁrst diagnosis of ITP were excluded. For each ITP
case up to ﬁve, non-ITP patients (controls) were matched on
practice,age,gender,andfollow-upperiod.Theindexdateof
a case was the ﬁrst ITP diagnosis date, while that of a control
was the index date of his/her matched ITP case. Potential
controls also had to have at least one medical record or a
recorded prescription in the database within one year before
or one year after the ITP diagnosis date.
Potentialcomorbiditieswereallmedicalconditionslisted
in the GPRD of the cases and/or controls at preferred term
level (PTL) of the medical dictionary for regulatory activities
(MedDRA) hierarchical classiﬁcation, over the period of a
year before and a year after index date. Additionally, seven
selected grouped medical conditions of a priori interest were
deﬁned and considered: myocardial infarction, breast cancer,
chronic renal failure, hepatitis, liver damage, systemic lupus,
and thromboembolic events.
Becausetheperiod1yearbeforeand1yearaftertheindex
date can lead to bias due to diﬀerential medical screening
between cases and controls [27], the relative frequency of
comorbidity between case and controls was further assessed
by considering a longer follow-up period. Hence, over the
period of 5 years before and 5 years after the index date,
trends in risks and risk ratios of identiﬁed comorbidities
were explored. However, in this latter analysis, in order
to reduce the list of considered medical conditions to
a manageable size, identiﬁed conditions at the preferred
term level were grouped in a clinical meaningful way by a
clinical epidemiologist with a good knowledge of the UK
health system. This pooling of medical conditions into more
aggregate groups (hereafter 26 grouped medical conditions)
also increases the power of any comparison between cases
and controls with respect to the frequency occurrence of
any potential comorbidity. Indeed, because in this analysis
we were only interested in the ﬁrst occurrence of potential
comorbidities, over the course of the follow-up period, small
sample size was an issue. This is the case, particularly for rare
conditions.
2.3. Statistical Analysis. Age and gender characteristics of
ITP patients together with the number of controls per case
were described using frequency tables. For each comorbidity,
the frequency of its occurrence in cases was compared to
that in controls using odds ratios calculated by conditional
logistic regression [28]. All medical conditions with odds
ratios greater than or equal to 2 and statistically signiﬁcant
at the 0.1% level were selected, ranked by odds ratios and
reported. The sensitivity of our chosen signiﬁcance level of
0.1% to the risk of false positives due to multiple testing was
assessed using false discovery rate procedure (FDR) [29].
Trends for each comorbidity over the 10-year period
were explored using annual incidence rates (calculated as
the number of events over person-years at risk) and rate
ratios(with95%conﬁdenceintervals)betweenITPandnon-
ITP patients. Conﬁdence intervals were calculated using theAdvances in Hematology 3
Table 1: ITP patients by age and gender.
Age (years) Gender Total N (%∗)
Female n (%∗)M a l e n (%∗)
0–15 94 (16.3) 131 (28.8) 225 (21.7)
16–49 208 (36.0) 95 (20.9) 303 (29.3)
50 + 276 (47.7) 229 (50.3) 505 (49.9)
Total 578 (100.0) 455 (100.0) 1033 (100.0)
∗Proportions are column proportions.
Table 2: Distribution of number of controls per case.
Number of
controls
per case
Frequency (cases) Percent Cumulative percent
0 150 14.5 14.52
1 64 6.20 20.72
2 39 3.78 24.49
3 68 6.58 31.07
4 206 19.9 51.02
5 506 49.0 100.00
Clayton and Hills formula [30]. To complement the analysis
ofannualincidencerates,acumulativeriskanalysis[31]o v er
the 5-year post index period for each of the comorbidities
is performed using log rank test. All analyses are performed
using SAS version 9.1.
3. Results
3.1. Description of Cases and Controls. A total of 1033 inci-
dent physician-diagnosed ITP cases during the period 1990–
2004 were identiﬁed, 578 (56.0%) of whom were females.
Table 1 presents the distribution of these patients by age,
group, and gender. Approximately, 50% are 50 or over. Mean
age was 46 in females and 44 years in males. Following
matching, 883 cases (85.5%) had at least one matched
control, and these 883 cases were used in further analyses.
A total of 3700 controls were selected, and Table 2 presents
the distribution of number of controls per case, 69% of cases
had 4 or 5 controls.
ITP patients and their matched controls had a total
2366 unique medical conditions at the PTL of the MedDRA
classiﬁcation. Figure 1 and Table 3 show medical conditions
with an odds ratio (OR) greater than 2 and signiﬁcant at
the 0.1% level. Conditions are sorted in descending order of
OR. Clinical signs or symptoms known to characterize ITP
a r es t r o n g l ya s s o c i a t e dw i t hI T P( i . e . ,p u r p u r a ,O R= 146;
bruise, OR = 57; neutropenia, OR = 29; etc.). There is a
strong association between ITP and death (OR = 60.0; 95%
CI [4.47–806.0]). It is also important to note that more than
90 conditions are associated with ITP in this analysis despite
our use of stringent criteria (i.e., an odds ratio greater than
2 and statistically signiﬁcant at a 0.1% level). The use of the
false discovery rate procedure to control for the increasing
risk of false positives due to multiple testing indicates that
setting the signiﬁcance level of each individual test at 0.35%
would have guaranteed a targeted overall 5% level. So, our
choice of 0.1% as a signiﬁcance level is on the cautious side
with respect to expected false positives. As noted above, all
of these signiﬁcant conditions were grouped into 26 broader
conditions as shown in Table 4.
Some of the medical conditions are rare and/or only
found in the ITP group. Because of this, odds ratios, even
though quite large (i.e., >2), they may not be statistically
signiﬁcant. Medical conditions with odds ratios greater
than 2 but with no more than one event in the control
group are thrombocytopenia, petechiae, splenectomy, pur-
pura, haemorrhagic disorder, sepsis, bronchopneumonia,
headaches, gingival, guttate psoriasis, acute pancreatitis,
pleural eﬀusion, restlessness, and somnolence.
3.2. Longitudinal Approach and Cumulative Risk Analysis for
Grouped Conditions. Table 5 presents, for each of the 26
groupedmedicalconditions,overaperiodof10yearsaround
theindexdate,yearlyincidencerateratios,betweencasesand
controls, and their 95% CI. Results can be summarized as
follows.
(i) Conditions that have a signiﬁcantly higher frequency
of occurrence in ITP compared to non-ITP in at
least one time period both before and after diagnosis:
haematological diseases, dermatological conditions,
bleeding disorders, gastrointestinal diseases, autoim-
mune disorders, and constitution conditions.
(ii) Conditions that have signiﬁcantly higher frequency
of occurrence in ITP compared to non-ITP patients
only after index date: oral conditions and infections.
(iii) Conditions that have signiﬁcantly higher frequency
of occurrence in ITP compared to non-ITP patients
duringonlytheyearofITPdiagnosisorayearbefore:
neurological, coronary artery syndrome/myocardial
infarction, genitourinary, musculoskeletal, ophthal-
mologic, skeletal, and edema.
(iv) Other conditions with no statistical association with
ITP.
None of the conditions was found to have a negative
association with ITP.
The analysis of conditions of a priori interest (the 7
grouped comorbidities) shows that over the 10-year period,
none of the annual incidence rate ratios of the conditions
breast cancer, liver disease, viral hepatitis, and thromboem-
bolic events was statistically diﬀe r e n tf r o mo n e ,a tt h e5 %
level (Table 6). This suggests that there is no evidence of
an association with ITP. However, there was a suggestion
of an association between ITP and myocardial infarction
during the last 2 years before ITP diagnosis (RR = 3.63 and
RR = 4.69, resp., see Table 6)). There was also evidence of
an association between ITP and chronic renal failure during
years 4 and 5 after the index date (RR = 6.21 and RR = 6.54,
resp.). Although rare (9 total number of observed events),
systemic lupus occurred in ITP patients only (i.e., was not
observed in control patients), which suggests an association
between ITP and systemic lupus (Table 6). Figure 2 shows,
for each of the 7 grouped comorbidities, the evolution of4 Advances in Hematology
Table 3: Comorbidities signiﬁcantly associated with ITP in the period or 2 years around diagnosis date.
P Odds ratio CL Preferred term name P Odds ratio CL Preferred term name
<.0001 146.00 23.48 907.97 Purpura .0009 3.30 1.30 8.36 Breast cancer female NOS
<.0001 146.00 23.48 907.97 Purpura NOS .0009 3.30 1.30 8.36 Condition aggravated
<.0001 60.00 4.47 805.56 Death .0008 3.18 1.31 7.75 Haemoptysis
<.0001 60.00 4.47 805.56 Death NOS .0008 3.18 1.31 7.75 Confusion
<.0001 57.33 19.85 165.60 Increased tendency to bruise <.0001 3.17 1.58 6.35 Diabetes mellitus noninsulin-dependent
.0009 29.00 2.11 398.24 Neutropenia <.0001 3.17 1.58 6.35 Diabetes mellitus noninsulin-dependent
<.0001 21.50 3.34 138.56 Whole blood transfusion <.0001 3.14 1.65 5.99 Prostatism
<.0001 17.31 10.84 27.65 Ecchymosis .0001 2.94 1.43 6.06 Left ventricular failure
<.0001 15.63 9.97 24.49 Contusion .0008 2.92 1.28 6.69 Respiratory disorder
.0006 12.50 1.88 82.96 Chills .0008 2.92 1.28 6.69 Respiratory disorder NOS
.0006 12.50 1.88 82.96 Rigors .0004 2.81 1.33 5.95 Analgesic eﬀect
<.0001 11.00 2.33 51.99 Chemoprophylaxis NOS <.0001 2.73 1.51 4.93 Vaginal haemorrhage
<.0001 11.00 2.33 51.99 Prophylactic chemotherapy .0005 2.71 1.30 5.62 Dermatitis diaper
<.0001 9.50 2.45 36.79 Haematemesis .0007 2.69 1.26 5.71 Phlebitis NOS
<.0001 8.43 4.07 17.46 White blood cell disorder <.0001 2.67 1.44 4.94 Oral candidiasis
<.0001 8.43 4.07 17.46 White blood cell disorder NOS .0002 2.65 1.35 5.21 Postoperative analgesia
<.0001 7.57 2.69 21.33 Pneumonia <.0001 2.61 1.54 4.42 Iron deﬁciency anaemia
<.0001 7.57 2.69 21.33 Pneumonia NOS <.0001 2.59 1.58 4.27 Anaemia
<.0001 7.00 2.04 23.98 Blister <.0001 2.59 1.58 4.27 Anaemia NOS
<.0001 7.00 1.77 27.74 Dry mouth <.0001 2.59 1.45 4.65 Osteoporosis
<.0001 6.90 2.89 16.50 Leg ulcer (exc varicose) <.0001 2.59 1.45 4.65 Osteoporosis NOS
<.0001 6.90 2.89 16.50 Leg ulcer (excl varicose) <.0001 2.58 1.42 4.67 Dry eye NEC
<.0001 6.82 4.05 11.49 Epistaxis <.0001 2.58 1.42 4.67 Dry eye NOS
.0009 6.00 1.49 24.12 Dementia <.0001 2.57 1.45 4.56 Keratoconjunctivitis sicca
.0009 6.00 1.49 24.12 Dementia NOS .0005 2.50 1.26 4.94 Lethargy
.0009 6.00 1.49 24.12 Decubitus ulcer <.0001 2.44 1.47 4.07 General symptom
.0009 6.00 1.49 24.12 Pressure sore <.0001 2.44 1.47 4.07 General symptom NOS
.0004 5.60 1.60 19.56 Venesection <.0001 2.44 1.53 3.89 Rectal haemorrhage
.0004 5.60 1.60 19.56 Venipuncture .0004 2.37 1.27 4.44 Mouth ulceration
<.0001 5.55 2.39 12.89 Peripheral swelling .0004 2.31 1.26 4.23 Cardiac failure congestive
<.0001 5.53 2.80 10.90 Eczema gravitational .0008 2.30 1.21 4.38 Cerebrovascular accident
<.0001 5.53 2.80 10.90 Stasis dermatitis <.0001 2.27 1.60 3.22 Oedema peripheral
<.0001 5.50 2.27 13.33 Acute myocardial infarction .0008 2.24 1.21 4.16 Gastro-oesophageal reﬂux disease
.0005 5.40 1.54 18.92 Intermittent claudication .0008 2.24 1.21 4.16 Gastro-oesophageal reﬂux disease
<.0001 5.00 1.95 12.80 Abdominal pain lower <.0001 2.21 1.58 3.10 Viral infection
.0003 5.00 1.58 15.82 Hip arthroplasty <.0001 2.21 1.58 3.10 Viral infection NOS
<.0001 4.71 2.21 10.06 Myocardial infarction <.0001 2.21 1.70 2.87 Rash
<.0001 4.24 2.39 7.52 Feeling abnormal <.0001 2.21 1.70 2.87 Rash NOS
<.0001 3.95 2.11 7.41 Skin ulcer <.0001 2.15 1.31 3.52 Menorrhagia
<0.0001 3.71 1.71 8.07 Dry eye <.0001 2.13 1.38 3.29 Diabetes mellitus
.0006 3.67 1.39 9.66 Folliculitis <.0001 2.13 1.38 3.29 Diabetes mellitus NOS
<.0001 3.64 1.67 7.92 Acarodermatitis .0004 2.12 1.23 3.65 Haematuria
<.0001 3.64 1.67 7.92 Scabies infestation <0.0001 2.12 1.36 3.30 Haemorrhoids
<.0001 3.60 1.43 9.04 Angina unstable <.0001 2.08 1.33 3.26 Prophylaxis
<.0001 3.35 2.23 5.03 Malaise <.0001 2.08 1.33 3.26 Prophylaxis NOS
.0009 3.30 1.30 8.36 Oral pain .0002 2.02 1.24 3.29 Atrial ﬁbrillationAdvances in Hematology 5
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Figure 1: Medical conditions with OR signiﬁcantly greater than 2 but less than 20.
Table 4: Comorbidities at the PTL of the MedDRA classiﬁcation and their 26 grouping.
Grouped conditions Medical conditions at preferred term level
Bleeding
Ecchymosis, haemoptysis, conjunctival haemorrhage, menorrhagia, rectal
haemorrhage, gastrointestinal haemorrhage NOS
∗, haematuria, epistaxis,
haematemesis
Pulmonary Respiratory disorder, respiratory disorder NOS
∗
Constitution Chills, rigors, malaise, general symptom, feeling abnormal, lethargy
Peripheral vascular diseases Phlebitis NOS, aortic aneurysm, phlebitis, intermittent claudication
Cerebrovascular accident Cerebrovascular accident
Haematology White blood cell disorder, white blood cell disorder NOS, neutropenia, anaemia,
iron deﬁciency anaemia, anaemia NOS
Arrhythmia Atrial ﬁbrillation
Autoimmune Systemic lupus erythematosus, rheumatoid arthritis
Renal Renal failure acute
Infection Viral infection, pneumonia, viral infection NOS, pneumonia NOS
Oral conditions Oral candidiasis, dry mouth, mouth ulceration, oral pain
Hypoglycemia Hypoglycaemia, hypoglycaemia NOS
Neoplasm malignant Neoplasm malignant
Dermatological conditions
Leg ulcer (exc varicose), rash scaly, skin exfoliation, eczema gravitational, stasis
dermatitis, decubitus ulcer, pressure sore, folliculitis, skin ulcer, tinea NOS, rash,
infected sebaceous cyst, dermatitis diaper, rash NOS
Hypersensitivity Hypersensitivity, hypersensitivity NOS
Breast cancer Breast cancer female NOS, breast cancer, breast cancer NOS
Neurology Confusional state, dementia, dementia NOS, confusion
Diabetes Diabetes mellitus noninsulin-dependent, diabetes mellitus noninsulin-dependent,
diabetes mellitus, diabetes mellitus NOS
Edema Peripheral swelling, oedema peripheral
Genitourinary Prostatism, proctalgia
Coronary artery syndrome/myocardial infarction Acute myocardial infarction, myocardial infarction, angina unstable
Congestive heart failure Left ventricular failure, cardiac failure congestive
Gastro intestinal Haemorrhoids, abdominal pain lower, gastro-oesophageal reﬂux disease,
gastro-oesophageal reﬂux disease, colitis, colitis NOS
Ophthalmology Dry eye NEC, dry eye, eyelid ptosis, eye pain, dry eye NOS, keratoconjunctivitis
sicca
Musculo-skeletal conditions Osteoporosis, hip arthroplasty, ligament sprain, musculoskeletal pain, osteoporosis
NOS
Mood disorder Dysthymic disorder
∗Not otherwise speciﬁed.6 Advances in Hematology
Table 5: Rate ratios and 95% CI between ITP and non-ITP patients for 26 grouped medical conditions.
(a)
Comorbidity group Ratio ITP/non-ITP
[−5 −4[ [−4 −3[ [3 −2[ [−2 −1[ [−1 diag[
Rate
ratio
Lower
CI
Upper
CI
Rate
ratio
Lower
CI
Upper
CI
Rate
ratio
Lower
CI
Upper
CI
Rate
ratio
Lower
CI
Upper
CI
Rate
ratio
Lower
CI
Upper
CI
CASMI 1.4 0.3 7.4 0.9 0.2 4.3 2.7 0.9 7.8 3.1 1.0 9.3 4.0 1.7 9.5
PVD 1.7 0.6 4.8 1.1 0.3 4.0 3.0 0.9 10.0 4.6 1.8 11.6 1.5 0.5 4.4
Heme 2.8 1.3 5.7 2.2 1.0 5.0 3.0 1.4 6.2 2.1 1.1 4.0 4.9 3.2 7.6
Renal NA — — 0.0 — — NA — — 3.6 0.2 57.3 7.2 0.7 79.1
Pulmonary 12 0.1 11.5 0.0 — — 7.2 0.7 79.1 4.8 1.1 21.4 1.2 0.3 4.4
Oral 1.4 0.7 2.7 1.5 0.7 3.2 0.9 0.4 2.2 1.1 0.6 2.2 2.8 1.4 5.3
Ophthalmologic 2.3 0.9 5.9 1.4 0.5 3.9 1.3 0.5 3.2 1.5 0.7 3.5 2.6 1.2 5.4
Neurological 0.0 — — 0.7 0.1 6.1 3.6 0.5 25.4 4.8 1.1 21.4 7.2 1.8 28.8
Neoplasm 3.6 0.2 57.4 1.8 0.2 19.8 NA — — 0.0 — — 0.7 0.1 6.1
Musculo-skeletal 1.6 0.7 3.7 1.0 0.3 3.1 1.3 0.6 3.2 1.4 0.5 3.5 2.6 1.3 5.3
Mood disorder 1.8 0.4 7.2 0.0 — — 3.6 0.2 57.3 0.0 — — Inf — —
Infections 1.3 0.6 2.8 1.3 0.6 2.8 1.4 0.6 2.9 1.4 0.8 2.5 2.9 1.8 4.6
Hypoglycemia 0.0 — — NA — — Inf — — 0.0 — — 3.6 0.2 57.3
Hypersensitivity 4.8 1.1 21.4 1.4 0.3 7.4 2.7 0.6 12.1 0.0 — — 0.7 0.2 3.3
GU 3.6 0.7 17.8 1.2 0.3 4.4 2.1 0.6 7.0 0.4 0.1 2.0 1.0 0.3 3.1
GI 0.9 0.4 2.3 1.4 0.7 2.7 0.9 0.4 2.0 1.8 1.0 3.0 2.4 1.5 3.9
Edema 1.6 0.6 3.8 1.5 0.6 3.6 0.6 0.2 1.7 1.8 0.8 3.8 1.5 0.8 2.7
Diabetes 1.4 0.5 3.9 0.9 0.3 2.5 1.8 0.6 5.3 1.5 0.6 3.3 1.6 0.7 3.4
Derm 1.1 0.6 1.9 1.5 1.0 2.3 1.2 0.8 1.9 1.6 1.0 2.3 2.5 1.9 3.3
CV 0.0 — — 3.6 0.5 25.4 2.2 0.5 9.0 1.8 0.3 9.8 4.3 1.3 14.1
Constitution 1.4 0.6 3.1 1.3 0.7 2.5 2.3 1.2 4.2 1.7 1.0 3.0 2.8 1.8 4.6
CHF 0.0 — — 2.2 0.5 9.0 1.1 0.3 3.9 2.7 0.9 7.8 1.0 0.3 3.1
Breast cancer 3.6 0.2 57.1 0.9 0.1 8.0 NA — — 1.8 0.3 9.8 1.8 0.3 9.8
Bleeding 1.3 0.8 2.1 1.6 1.0 2.7 1.8 1.2 2.8 2.2 1.5 3.3 9.0 6.8 11.9
Autoimmune 3.6 0.7 17.9 5.4 0.9 32.6 Inf — — 1.2 0.1 11.7 6.1 1.5 25.4
Arrhythmia 0.7 0.2 3.3 0.0 — — 0.3 0.0 2.0 0.7 0.2 3.3 3.6 1.4 9.1
(b)
Comorbidity group Ratio ITP/non-ITP
[diag +1[ [+1 +2[ [+2 +3[ [+3 +4[ [+4 +5[
Rate
ratio
Lower
CI
Upper
CI
Rate
ratio
Lower
CI
Upper
CI
Rate
ratio
Lower
CI
Upper
CI
Rate
ratio
Lower
CI
Upper
CI
Rate
ratio
Lower
CI
Upper
CI
Ntotal
ITP/
year
CASMI 1.9 0.7 5.6 0.9 0.2 4.1 2.0 0.5 8.0 1.0 0.1 9.3 4.4 0.9 21.6 4.1
PVD 3.4 1.2 9.4 0.5 0.1 2.4 2.4 0.9 6.7 1.7 0.3 8.7 1.8 0.3 9.2 4.7
Heme 3.8 2.2 6.6 2.4 1.3 4.5 5.9 3.0 11.6 2.0 0.8 5.2 0.8 0.2 2.7 16.4
Renal Inf — — Inf — — 0.0 — — 0.0 — — 4.3 0.3 68.8 0.7
Pulmonary 3.8 0.9 15.1 2.5 0.8 7.6 0.8 0.1 6.8 0.8 0.1 7.1 0.7 0.1 6.0 2.2
Oral 3.6 1.9 6.8 3.1 1.5 6.4 0.5 0.1 2.2 1.8 0.6 5.0 1.0 0.3 3.6 9.5
Ophthalmologic 2.8 1.4 5.7 0.9 0.3 2.8 1.1 0.3 3.9 0.9 0.3 3.1 1.3 0.4 4.1 6.5
Neurological 2.4 0.9 6.2 0.2 0.0 1.7 1.8 0.5 5.7 2.7 0.8 9.7 0.6 0.1 5.0 3.0
Neoplasm Inf — — 0.0 — — 8.0 0.7 87.8 0.0 — — 0.0 — — 1.0
Musculo-skeletal 3.8 2.1 7.0 1.6 0.6 4.2 1.4 0.4 4.2 1.7 0.7 4.4 0.8 0.2 3.7 7.7
Mood disorder 1.9 0.2 20.7 0.0 — — 0.0 — — 4.1 0.3 64.9 Inf — — 0.8Advances in Hematology 7
(b) Continued.
Comorbidity group Ratio ITP/non-ITP
[diag +1[ [+1 +2[ [+2 +3[ [+3 +4[ [+4 +5[
Rate
ratio
Lower
CI
Upper
CI
Rate
ratio
Lower
CI
Upper
CI
Rate
ratio
Lower
CI
Upper
CI
Rate
ratio
Lower
CI
Upper
CI
Rate
ratio
Lower
CI
Upper
CI
Ntotal
ITP/
year
Infections 1.9 1.2 3.1 1.7 0.9 3.0 2.2 1.1 4.2 2.0 0.8 4.5 0.5 0.1 2.0 13.5
Hypoglycemia 5.7 0.9 33.8 2.0 0.2 21.8 2.6 0.4 15.8 0.0 — — NA — — 0.8
Hypersensitivity 4.3 1.6 11.9 2.0 0.5 7.9 0.7 0.1 3.0 0.0 — — 0.0 — — 2.4
GU 3.5 1.5 7.9 2.2 0.8 5.9 0.7 0.1 3.0 1.4 0.4 5.1 2.9 0.5 17.3 4.0
GI 2.0 1.1 3.8 1.2 0.6 2.2 1.9 1.0 3.7 0.7 0.3 1.8 2.7 1.2 6.1 12.7
Edema 2.4 1.4 3.9 0.6 0.2 1.6 0.2 0.1 0.9 0.9 0.3 2.3 0.7 0.2 2.3 8.4
Diabetes 2.1 0.8 5.2 1.0 0.3 3.0 1.2 0.3 4.3 1.2 0.2 5.7 0.7 0.1 5.9 4.8
Derm 2.5 1.8 3.6 1.0 0.7 1.6 1.6 1.0 2.6 1.3 0.8 2.4 0.9 0.4 1.9 30.1
CV 1.9 0.7 5.0 0.7 0.1 2.9 2.2 0.7 6.6 0.0 — — 1.2 0.3 6.0 2.8
Constitution 2.3 1.6 3.5 1.1 0.7 1.9 1.8 1.0 3.3 1.6 0.8 3.1 1.2 0.5 3.1 17.6
CHF 1.5 0.7 3.4 0.7 0.1 2.9 0.9 0.2 4.1 0.4 0.1 3.2 0.6 0.1 4.9 3.0
Breast cancer 0.0 — — 0.0 — — 0.0 — — Inf — — 0.0 — — 0.8
Bleeding 2.9 2.0 4.1 3.9 2.6 5.7 1.7 1.0 3.0 0.7 0.3 1.7 2.3 1.3 4.2 40.1
Autoimmune 15.4 1.7 137.5 2.0 0.4 11.0 12.2 1.3 117.2 2.1 0.2 23.3 0.0 — — 2.3
Arrhythmia 1.6 0.7 3.6 0.0 — — 1.6 0.3 8.1 0.2 0.0 1.6 0.0 — — 2.5
Table 6: Yearly incidence rates ratios between ITP and non-ITP and their 95% conﬁdence interval of 7 comorbidities of priori interest.
(a)
Comorbidity group Ratio ITP/non-ITP
[−5 −4[ [−4 −3[ [3 −2[ [−2 −1[ [−1 diag[
Rate
ratio
Lower
CI
Upper
CI
Rate
ratio
Lower
CI
Upper
CI
Rate
ratio
Lower
CI
Upper
CI
Rate
ratio
Lower
CI
Upper
CI
Rate
ratio
Lower
CI
Upper
CI
MI 0.9 0.10 8.10 0.6 0.07 5.0 2.6 0.8 8.1 3.6 1.0 12.5 4.7 1.7 12.6
Breast cancer 1.8 0.2 19.7 0.9 0.1 8.0 0.0 — — 1.4 0.3 7.3 2.1 0.5 8.9
Chronic renal failure 1.8 0.3 9.8 1.2 0.12 11.5 0.9 0.1 8.0 2.7 0.6 12.1 2.6 0.8 8.1
Viral hepatitis 1.2 0.7 2.2 1.5 0.8 2.6 0.9 0.5 1.5 0.7 0.4 1.4 0.7 0.4 1.25
Liver damage ———————————————
Systemic lupus 1.8 0.2 19.8 NA — — 3.6 0.2 57.4 NA — — Inf ——
Thrombo-embolic 1.2 0.1 11.5 0.9 0.1 8.1 1.03 0.21 4.9 7.2 1.3 39.4 1.4 0.4 5.1
(b)
Comorbidity group Ratio ITP/non-ITP
[diag +1[ [+1 +2[ [+2 +3[ [+3 +4[ [+4 +5[
Rate
ratio
Lower
CI
Upper
CI
Rate
ratio
Lower
CI
Upper
CI
Rate
ratio
Lower
CI
Upper
CI
Rate
ratio
Lower
CI
Upper
CI
Rate
ratio
Lower
CI
Upper
CI
MI 3.18 0.97 10.4 1.14 0.2 5.5 2.4 0.6 10.1 1.0 0.1 9.3 4.4 0.9 21.6
Breast cancer 0.9 0.1 8.4 0.0 — — 0.0 — — inf — — 2.15 0.2 23.7
Chronic renal failure 3.0 0.8 11.3 0.0 ——1.9 0.5 7.9 6.2 1.04 37.1 6.5 1.1 39.1
Viral hepatitis 0.6 0.3 1.2 0.8 0.4 1.6 0.7 0.3 1.7 1.2 0.6 2.3 1.3 0.5 3.2
Liver damage ———————————————
Systemic lupus Inf —— Inf —— N A —— N A —— Inf ——
Thrombo-embolic 1.3 0.3 6.3 1.2 0.3 4.3 0.0 — — 0.8 0.1 7.1 1.7 0.3 8.98 Advances in Hematology
Table 7: One- and ﬁve-year risk of 26-grouped comorbidities and tests over strata after index.
Comorbidities
grouped
Test over strata ITP/non-ITP ITP cohort n = 883 Non-ITP cohort n = 3700
log-rank
∗ N Nb comor b 1-year risk 5-year risk N Nb comor b 1-year risk 5-year risk
Coronary artery
syndrome/myocardial
infarction
NS 982 15 0.63% 1.95% 3601 47 0.25% 1.12%
Peripheral vascular
diseases
NS 976 22 0.85% 2.86% 3598 60 0.19% 1.45%
Haematological
conditions
S 912 90 0.00% 12.59% 3478 149 0.00% 4.37%
Autoimmune S 1004 13 0.50% 1.39% 3662 14 0.03% 0.28%
Renal NS 1030 4 0.20% 0.58% 3696 5 0.00% 0.08%
Pulmonary NS 1022 16 0.42% 1.58% 3678 45 0.11% 1.06%
Oral S 953 51 2.06% 5.76% 3468 122 0.61% 2.98%
Ophthalmologic NS 974 32 1.40% 3.81% 3546 97 0.42% 2.88%
Neurological NS 1021 24 0.80% 2.53% 3682 72 0.27% 1.82%
Neoplasm S 1026 7 0.51% 0.76% 3685 10 0.00% 0.31%
Musculo-skeletal S 974 51 2.04% 5.17% 3540 113 0.59% 2.78%
Mood disorder NS 1021 4 0.10% 0.29% 3661 13 0.05% 0.28%
Infections S 946 77 2.52% 8.78% 3503 203 1.37% 5.58%
Hypoglycemia NS 1030 8 0.30% 0.69% 3696 15 0.05% 0.33%
Hypersensitivity NS 1008 18 0.00% 2.13% 3630 49 0.00% 1.77%
Genitrourinary S 1000 28 1.03% 3.19% 3597 59 0.31% 1.65%
GastroIntestimnal NS 907 64 1.96% 8.76% 3324 216 0.81% 5.52%
Edema NS 970 53 2.58% 5.24% 3508 198 1.08% 5.50%
Diabetes NS 972 21 0.74% 2.26% 3546 68 0.33% 2.89%
Dermatological
conditions
S 788 158 7.19% 20.66% 3107 493 2.67% 13.87%
Cerebrovascular
conditions
NS 1015 18 0.62% 2.00% 3661 56 0.30% 1.53%
Constitution S 916 109 0.00% 14.98% 3425 299 0.00% 9.50%
Congestive heart
failure
NS 1010 17 0.81% 1.82% 3636 70 0.52% 2.05%
Breast cancer NS 1025 3 0.00% 0.30% 3670 15 0.00% 0.44%
Bleeding S 671 167 9.23% 27.82% 3059 498 2.55% 11.91%
Arrhythmia NS 1006 14 0.82% 2.32% 3629 81 0.52% 2.32%
∗NS = Not signiﬁcant at 5% level; S = Signiﬁcant at 5% level.
their cumulative risk over time (i.e., the overall risk over
a speciﬁc length of time). Table 7 presents the one- and 5-
year risk of all 26 grouped comorbidities together with a log-
rank test of diﬀerence of occurrence between ITP and non-
ITP. These latest analyses further suggest ITP association
with medical conditions: neoplasm, constitution, after index
date.Theseassociationswerenotobservedinearlieranalyses,
probably because of insuﬃcient numbers.
4. Conclusion/Discussion
We report here an extensive database exploration of med-
ical conditions associated with ITP. First, comparing the
frequency of occurrence of each considered disorder in
ITP patients and their matched controls, we systematically
selected all medical conditions that are likely to be associated
with ITP. Then, pooling those selected conditions into more
aggregated groups and exploring the trend in their yearly
relative frequency over a ten-year period helped us put
observed associations into perspective.
We found that ITP is associated with a considerable
number of medical conditions, a good number of which
to our knowledge were not systematically reviewed before.
The association between ITP and some of these conditions
(or group of conditions) is apparent both before and
after ITP diagnosis. These conditions are hematologicalAdvances in Hematology 9
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Figure 2: Cumulative risk of 7 grouped conditions over time in ITP and non-ITP populations.
diseases, dermatological conditions, bleeding disorders and
constitutionalconditions,forexample,chills,rigors,malaise,
and lethargy. The nature of these observed associations
suggests that either these conditions share similar causal
pathways as ITP or they predispose to the diagnosis of ITP.
There are also conditions associated with ITP only
after ITP diagnosis such as oral conditions, infections,
gastrointestinal, and autoimmune disorders. This could be
indicative of ITP being on the causal pathway of these
conditions, an adverse eﬀect of any of the medications
generally taken by ITP patients or were conditions not
screened for prior to diagnosis of ITP. Further studies are
needed here to disentangle the disease (ITP) eﬀect from
potential medication eﬀect and other contributing factors.
Conditions associated with ITP only during the years
around diagnosis are more likely to be a result of diagnosis
bias as mentioned earlier.
Strengths of the current study include design, simplicity,
large sample size, and its systematic nature. Indeed, ITP is
a relatively rare disease, and only large healthcare databases
with long follow-up such as the GPRD could provide an
appropriate base population. The design ﬁrst considers
cases and comparable controls and both a cross-sectional
and longitudinal approach. By comparing the frequency in
ITP patients of potential comorbidities to that in controls
matched in practice, gender and length of follow-up and
thus, computing the relative risk within the same study
base, numbers of confounders are controlled for, including10 Advances in Hematology
seasonality. We also systematically considered all medical
conditions on patients’ medical records as potential comor-
bidities. This is an important consideration for a hypothesis
generative study such as this.
A potential limitation of this research is perhaps our
subjective grouping of conditions at the preferred term
level, in order to obtain aggregated and thus more preva-
lent groups. We believe, however, that the diﬀerences in
potential grouping would be unlikely to strongly impact the
conclusions. Our attempts at using a more automated and
systematic grouping, such as a higher than PTL level of the
MedDRA classiﬁcation, proved diﬃcult, mainly because of
the overlapping nature of groups at the higher level of the
MedDRA classiﬁcation.
Children and adults were mixed. Childhood and adult-
hoodITPmaydiﬀersigniﬁcantly,andascomorbiditiesinthe
two age groups, it is arguable that a separate analysis of each
age group could have added potentially useful information
on the age grouping of identiﬁed comorbidities. However,
we believe that given the reduced number of ITP cases,
stratifying our sample into adults and children, there would
be less power to detect some of the comorbidities and
thus may not be able to identify some of the comorbidities
identiﬁed when the groups were combined.
Selection bias is also a concern. Within the current
design, although the use of a registration period of at least
1 year before any investigation maybe considered standard in
database observational research and increases the conﬁdence
thatnewreportsofadiseaserefertonewincidentconditions,
the requirement of having at least 1 year of enrollment after
identiﬁcationmayhavebiasedsomeestimates.Somepatients
because of the severity of their condition may have died
or been transferred within a year of their diagnosis. The
likelihood is that these patients had more comorbidities than
those not transferred or who did not die. The impact of
this is likely to result in an underestimate of the associations
observed. Other sources of bias include diﬀerential screening
between ITP and non-ITP patients. Patients with a diagnosis
of ITP might have a higher chance of receiving a diagnosis
of other disease due to regular follow-up GP visits. Thus,
the likely relation between GP consultation and frequency
of comorbidities imposes cautious interpretation of the
extensive list of conditions found here in association with
ITP, particularly for those associations only evident during
the years around diagnosis date.
Our stringent selection criteria also have limitations in
this study. Indeed, we may have missed some of the potential
comorbidities because either their OR was less than 2 or
the associated P-value was greater than 0.1%. Indeed, the
false discovery rate indicates that a signiﬁcant level for each
individual test of 0.32% would have guaranteed an overall
signiﬁcance level of 5%. These last two points may explain,
for example, why cataracts are not in our list of conditions
found in association with ITP. Indeed, oral corticosteroid
(OS) use is one of the ﬁrst line treatments of ITP, and it
is expected that a substantial number of our ITP patients
would be taking corticosteroids compared with non-ITP
patients [5]. A number of studies have consistently shown
an increased risk of cataracts associated with corticosteroid
use, although the risk is generally not found to be more than
two fold [32]. Our stringent criteria excluded comorbidities
with less than a two-fold increase in ITP patients compared
to non-ITP, as is the case of cataracts.
Another limitation of the current study is our choice
of the MedDRA classiﬁcation. Indeed, data in GPRD are
reported by physicians in READ or OXMIS codes and latter
mapped to MedDRA. Not all medical conditions would have
acorrespondentPTLoftheMedDRAclassiﬁcation.Thismay
only limits the number of potential comorbidities we could
explore. Indeed, there is no reason to believe that conditions
with no corresponding PTL on the MedDRA would be
systematically more frequent in cases compared to controls.
Thus, its impact is more likely to be on increasing the list
of potential comorbidities, rather than dismissing some of
those selected here.
We did not consider medication use, and thus our
analyses are not adjusted for this. Indeed, diseased patients
are likely to be taking medications, some of which are
associated with a higher risk of other conditions, as it is for
cataracts and corticosteroids. Hence, some of the observed
associations may be the result of medication use and/or
concomitant use of medications and not the result of the
condition itself. Also, age inﬂuences the pattern of ITP
expression [33] through its association with medication use,
including for cardiovascular conditions. Hence, some of the
identiﬁed comorbidities, rather than being directly linked
to ITP, may result from a complex interaction between
other comorbidities and/or medications used against these
comorbidities. Only speciﬁc and targeted studies would be
able to disentangle the eﬀects of medication, disease, and
other factors.
So, to conclude, two or more medical conditions can
cooccur because (1) there is a direct causal relationship
betweentheseconditions,wherebythepresenceofonemakes
the other more likely to develop, (2) there is an indirect
causal relationship between the two conditions, whereby
one condition aﬀects a third variable in a way that makes
the second condition more likely to develop, (3) there are
common factors that increase the risk of both disorders,
(4) the occurrence of one of the medical conditions is
associated with medication used to treat the other, or (5)
other reasons [34]. The diagnosis of ITP is complex and
based on exclusion of other causes of thrombocytopenia.
There is also relatively little epidemiological evidence on the
disease. To the best of our knowledge, this is the ﬁrst study
using large healthcare databases to systematically explore
comorbidities of ITP. This study aimed to support what we
knowandthenpotentiallygleanadditionalinsightsfromthis
rich data source, which might then trigger further interest in
setting up additional speciﬁc focused studies. This should be
done in a variety of settings. These targeted studies should
also help the understanding of the underlying mechanism.
The current exploration suggests that ITP, despite being a
rare disease, is associated with a considerably higher level of
mortality risk as well as an extensive list of comorbid medical
conditions. For ITP patients, this increased quantitative
understanding of ITP comorbidities hopefully may assist in
improved disease management of ITP patients.Advances in Hematology 11
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